Asthma Comparative Effectiveness Study

A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol Combination (BFC) and Fluticasone Propionate/Salmeterol Combination (FSC) Among Asthma Patients

The objective of this study is to compare the real-world effectiveness of BFC and FSC in asthma patients new to ICS/LABA combination therapy in a population of U.S. health plan enrollees.

A U.S. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients

Inclusion Criteria:

• Continuous health plan enrollment for 12 months before and after index Rx
• At least two prescription fills for BFC or FSC within 12 months
• Asthma claims diagnosis, and 12 to 64 years of age at the time of first prescription

Exclusion Criteria:

• Evidence of COPD
• Claims diagnosis of any of inflammatory diseases or cancer
• Presence of Rx for more than one type of ICS/LABA combination on index date
• Chronic steroid use or Xolair use prior to ICS/LABA index treatment